Patients with hemophilia A or B with inhibitors have a lower annualized bleeding rate with concizumab than with no prophylaxis, according to a phase 3 study published online Aug. 31 in the New England Journal of Medicine.
Tadashi Matsushita, M.D., Ph.D., from Nagoya University Hospital in Japan, and colleagues evaluated the safety and efficacy of concizumab in patients with hemophilia A or B with inhibitors. As part of the explorer7 phase 3 trial, participants were randomly assigned to receive no prophylaxis for at least 24 weeks (group 1; 19 patients) or to receive concizumab prophylaxis for at least 32 weeks (group 2; 33 patients), or they were nonrandomly assigned to receive concizumab prophylaxis for at least 24 weeks (groups 3 and 4; 81 patients).
The researchers found that the estimated mean annualized bleeding rate in group 1 was 11.8 episodes versus 1.7 episodes in group 2 (rate ratio, 0.14; P “Concizumab represents a novel, subcutaneous treatment option in patients with hemophilia A or B with inhibitors that can potentially improve long-term outcomes,” the authors write.
More information:
Tadashi Matsushita et al, Phase 3 Trial of Concizumab in Hemophilia with Inhibitors, New England Journal of Medicine (2023). DOI: 10.1056/NEJMoa2216455
H. Marijke van den Berg et al, Hemostasis—A Balancing Act, New England Journal of Medicine (2023). DOI: 10.1056/NEJMe2304535
Copyright © 2023 HealthDay. All rights reserved.
Citation:
Concizumab may be effective prophylaxis for hemophilia A or B with inhibitors (2023, September 3)
retrieved 3 September 2023
from https://medicalxpress.com/news/2023-09-concizumab-effective-prophylaxis-hemophilia-inhibitors.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no
part may be reproduced without the written permission. The content is provided for information purposes only.
